Krebs Biochemicals FY26 Loss Narrows to ₹1,693.31 lacs
Krebs Biochemicals & Industries Limited reported a narrowed net loss of ₹1,693.31 lacs for the fiscal year ended March 31, 2026, compared to a loss of ₹2,693.93 lacs in the previous year. Revenue from operations declined to ₹2,575.79 lacs from ₹4,402.08 lacs in FY25, while the company continues to face challenges with its Vizag manufacturing unit remaining closed.
*this image is generated using AI for illustrative purposes only.
Krebs Biochemicals & Industries Limited has released its audited standalone financial results for the fourth quarter and fiscal year ended March 31, 2026. The company reported a net loss of ₹233.96 lacs for the quarter and ₹1,693.31 lacs for the full year, reflecting continued financial challenges.
Financial Performance
Revenue from operations for the year ended March 31, 2026, stood at ₹2,575.79 lacs, a significant decrease from ₹4,402.08 lacs in the prior year. For the quarter ended March 31, 2026, revenue was recorded at ₹881.27 lacs. Total income for the year was ₹2,575.79 lacs, down from ₹4,402.08 lacs in FY25.
The company's total expenses for FY26 amounted to ₹4,269.10 lacs. Key expense components included finance costs of ₹708.59 lacs and employee benefits expenses of ₹1,038.80 lacs. Depreciation and amortisation expenses were reported at ₹642.33 lacs for the year.
Key Metrics
The board approved the financial results at its meeting held on May 21, 2026. The statutory auditors issued an unmodified report on the financial statements.
| Metric | FY26 (₹ in lacs) | FY25 (₹ in lacs) |
|---|---|---|
| Revenue from Operations | 2,575.79 | 4,402.08 |
| Total Income | 2,575.79 | 4,402.08 |
| Total Expenses | 4,269.10 | 7,094.48 |
| Net Profit/(Loss) | (1,693.31) | (2,693.93) |
| Earnings Per Share (Basic) | (7.85) | (12.49) |
Operational Status
The company noted that its Vizag manufacturing unit has remained closed following an order from the Andhra Pradesh Pollution Control Board dated February 7, 2025. Management stated that it is in constant dialogue with the authorities regarding the revocation of the closure order.
As of March 31, 2026, the company reported a negative net worth of ₹16,275.47 lacs. The debt-equity ratio was recorded at (1.38) times. The company's cash and cash equivalents decreased to ₹12.91 lacs from ₹14.16 lacs at the end of the previous year.
Historical Stock Returns for Krebs Biochemicals & Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.51% | +1.73% | +9.65% | -0.11% | -37.10% | -44.39% |
What specific remediation steps is Krebs Biochemicals undertaking to satisfy the Andhra Pradesh Pollution Control Board's requirements, and what is the realistic timeline for reopening the Vizag manufacturing unit?
Given the company's deeply negative net worth of ₹16,275.47 lacs and dwindling cash reserves, what debt restructuring or capital infusion strategies is management exploring to avoid insolvency proceedings?
How might the prolonged closure of the Vizag plant impact Krebs Biochemicals' key customer relationships and market share in the biochemicals sector, and can these be recovered once operations resume?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
